190 related articles for article (PubMed ID: 11718436)
1. Cox-2 inhibitors and cardiovascular risk: point and counterpoint.
Mandell BF
Cleve Clin J Med; 2001 Nov; 68(11):957-60. PubMed ID: 11718436
[No Abstract] [Full Text] [Related]
2. Cox-2 inhibitors and cardiovascular risk: the data are inconclusive, and these drugs are needed.
Lipani J
Cleve Clin J Med; 2001 Nov; 68(11):961-2. PubMed ID: 11718437
[No Abstract] [Full Text] [Related]
3. Cox-2 inhibitors and cardiovascular risk: we defend our data and suggest caution.
Mukherjee D; Nissen SE; Topol EJ
Cleve Clin J Med; 2001 Nov; 68(11):963-4. PubMed ID: 11718438
[No Abstract] [Full Text] [Related]
4. Why do COX-2 inhibitors increase risk of cardiovascular events?
Frankish H
Lancet; 2002 Apr; 359(9315):1410. PubMed ID: 11978344
[No Abstract] [Full Text] [Related]
5. Cardiovascular events and COX-2 inhibitors.
Minic M
JAMA; 2001 Dec; 286(22):2810; author reply 2811-2. PubMed ID: 11735746
[No Abstract] [Full Text] [Related]
6. [Cardiovascular ffects of COX-2 selective anti-inflammatory agents].
Halinen MO
Duodecim; 2001; 117(24):2570-1. PubMed ID: 12183817
[No Abstract] [Full Text] [Related]
7. COX 2 inhibitors may increase risk of heart attack.
Gottlieb S
BMJ; 2001 Sep; 323(7311):471. PubMed ID: 11532833
[No Abstract] [Full Text] [Related]
8. Cardiovascular events and COX-2 inhibitors.
Singh G
JAMA; 2001 Dec; 286(22):2810-1; author reply 2811-2. PubMed ID: 11735748
[No Abstract] [Full Text] [Related]
9. [COX-2 inhibitor to whom?].
Martio J
Duodecim; 2000; 116(12):1265-7. PubMed ID: 11988961
[No Abstract] [Full Text] [Related]
10. Risk of cardiovascular events associated with selective COX-2 inhibitors.
Mukherjee D; Nissen SE; Topol EJ
JAMA; 2001 Aug 22-29; 286(8):954-9. PubMed ID: 11509060
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular events and COX-2 inhibitors.
Grant KD
JAMA; 2001 Dec; 286(22):2809; author reply 2811-2. PubMed ID: 11735744
[No Abstract] [Full Text] [Related]
12. Cardiovascular events and COX-2 inhibitors.
White WB; Whelton A
JAMA; 2001 Dec; 286(22):2811-2. PubMed ID: 11735749
[No Abstract] [Full Text] [Related]
13. Cardiovascular events and COX-2 inhibitors.
Konstam MA; Demopoulos LA
JAMA; 2001 Dec; 286(22):2809; author reply 2811-2. PubMed ID: 11735743
[No Abstract] [Full Text] [Related]
14. Cardiovascular events and COX-2 inhibitors.
Haldey EJ; Pappagallo M
JAMA; 2001 Dec; 286(22):2809-10; author reply 2811-2. PubMed ID: 11735745
[No Abstract] [Full Text] [Related]
15. Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials.
Hawk ET; Viner JL; Umar A
Prog Exp Tumor Res; 2003; 37():210-42. PubMed ID: 12795057
[No Abstract] [Full Text] [Related]
16. Controversies in COX-2 inhibitor therapy: closing remarks.
Abramson SB; Furst DE; Hochberg MC; Patrono C
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S77-80. PubMed ID: 11695257
[No Abstract] [Full Text] [Related]
17. [The cardiovascular safety of cyclooxygenase-2 (COX-2) inhibitors].
Hasdai D; Gottlieb S; Godbourt U; Hod H; Kaluski E
Harefuah; 2002 Oct; 141(10):922-4. PubMed ID: 12420602
[No Abstract] [Full Text] [Related]
18. Cyclooxygenase-2 inhibitors in aspirin-sensitive asthma.
Passero M; Chowdhry S
Chest; 2003 Jun; 123(6):2155-6; author reply 2156. PubMed ID: 12796206
[No Abstract] [Full Text] [Related]
19. MI risk prompts rofecoxib withdrawal.
Thompson CA
Am J Health Syst Pharm; 2004 Nov; 61(21):2234-6, 2238. PubMed ID: 15552625
[No Abstract] [Full Text] [Related]
20. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
Atkinson HG
Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
[No Abstract] [Full Text] [Related]
[Next] [New Search]
